Mechanical Ventilation Clinical Trial
Official title:
Inspiratory Contribution of Pressure Support-ventilated Patients in Different PMI Conditions - a Prospective Physiological Study
Pressure support ventilation (PSV) is an assisted mechanical ventilation mode that provides synchronous inspiratory support for patients with spontaneous breathing. PSV divides the work involved in producing ventilation between the ventilator and the patients. The patient inspiratory effort needs close monitoring to avoid inappropriate assistance and maintain favorable patient-ventilator interaction during PSV. Esophageal pressure (Pes)-derived parameters are regarded as golden indicators of inspiratory effort. Based on this precondition, the fraction of PTP generated by the patient during PSV (PTP ratio) can evaluate the inspiratory contribution proportion of ventilated patients with spontaneous breathing. Inspiratory muscle pressure index (PMI) was confirmed to be associated with inspiratory effort and can effectively predict low/high effort. The study tries to explore the relationship between PMI and PTP ratio and find the optimal cut-off value of PMI to predict different PTP ratios. Second, investigators want to verify the safety and validity of PMI-guided PS settings for pressure-support ventilated patients.
Status | Recruiting |
Enrollment | 25 |
Est. completion date | August 7, 2023 |
Est. primary completion date | August 7, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: Adult acute respiratory failure patients undergoing mechanical ventilation were screened daily and enrolled 24 hours after switching to PSV mode. Exclusion Criteria: 1. age younger than 18 years old and more than 80 years old 2. chronic occlusive pulmonary diseases 3. known pregnancy and parturient 4. gastric, esophageal, and diaphragm surgery 5. barotrauma 6. neuromuscular diseases 7. intracranial hypertension and brain stem injury 8. consciousness level decreased (SAS less than 3 scores) 9. Anticipating withdrawal of life support and/or shift to palliation as the goal of care. |
Country | Name | City | State |
---|---|---|---|
China | Beijing Tiantan Hospital | Beijing |
Lead Sponsor | Collaborator |
---|---|
Jian-Xin Zhou |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The correlation between PMI and PTP ratio | Regression was conducted by the linear mixed-effects model with patients managed as random effects. The correlation between PMI and PTP ratio was evaluated as the coefficient of determination (R2). | 3 hours | |
Primary | The ability of PMI to detect different PTP ratios | The ability of PMI to detect different inspiratory effort contribution proportions was assessed using the Area Under the Receiver-Operating-Characteristics Curve (AUROC). The optimal cut-off values were selected based on the Youden index. | 3 hours | |
Secondary | Tidal volume per predicted body weight (VT/PBW, ml/Kg) | We use the VT/PBW (ml/Kg) as lung-protective ventilation safety makers. | 3 hours | |
Secondary | Respiratory rate (RR, circle/min) | We use the RR (circle/min) as lung-protective ventilation safety makers. | 3 hours | |
Secondary | Transpulmonary driving pressure (DPlung, cmH2O) | We use the DPlung (cmH2O) as lung-protective ventilation safety makers. | 3 hours | |
Secondary | Respiratory driving pressure (DPrs, cmH2O) | We use the DPrs (cmH2O) as lung-protective ventilation safety makers. | 3 hours | |
Secondary | Respiratory muscle pressure (Pmus, cmH2O) | Our study chose Pmus (cmH2O) as the golden standard of inspiratory effort to estimate the validity of PMI-guided PS setting. | 3 hours | |
Secondary | Esophageal pressure-time product (PTPes, cmH2O) | Our study chose PTPes (cmH2O) as the golden standard of inspiratory effort to estimate the validity of PMI-guided PS setting. | 3 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05921656 -
Construction and Evaluation of Airway Leakage Risk Model of Patients With Endotracheal Tube
|
||
Recruiting |
NCT03941002 -
Continuous Evaluation of Diaphragm Function
|
N/A | |
Withdrawn |
NCT04288076 -
The Brain and Lung Interaction (BALI) Study
|
N/A | |
Completed |
NCT03031860 -
Semi-quantitative Cough Strength Score (SCSS)
|
N/A | |
Completed |
NCT02312869 -
Local Assessment of Management of Burn Patients
|
N/A | |
Completed |
NCT02545621 -
A Role for RAGE/TXNIP/Inflammasome Axis in Alveolar Macrophage Activation During ARDS (RIAMA): a Proof-of-concept Clinical Study
|
||
Completed |
NCT01885442 -
TryCYCLE: A Pilot Study of Early In-bed Leg Cycle Ergometry in Mechanically Ventilated Patients
|
N/A | |
Completed |
NCT01204281 -
Proportional Assist Ventilation (PAV) in Early Stage of Critically Ill Patients
|
Phase 4 | |
Terminated |
NCT01059929 -
Dexmedetomidine Versus Propofol in the Medical Intensive Care Unit (MICU)
|
Phase 4 | |
Completed |
NCT00824239 -
Intermittent Sedation Versus Daily Interruption of Sedation in Mechanically Ventilated Patients
|
Phase 3 | |
Completed |
NCT00529347 -
Mechanical Ventilation Controlled by the Electrical Activity of the Patient's Diaphragm - Effects of Changes in Ventilator Parameters on Breathing Pattern
|
Phase 1 | |
Unknown status |
NCT00260676 -
Protective Ventilatory Strategy in Potential Organ Donors
|
Phase 3 | |
Terminated |
NCT00205517 -
Sedation and Psychopharmacology in Critical Care
|
N/A | |
Completed |
NCT03281785 -
Ultrasound of Diaphragmatic Musculature in Mechanically Ventilated Patients.
|
N/A | |
Recruiting |
NCT04110613 -
RCT: Early Feeding After PEG Placement
|
N/A | |
Completed |
NCT04410783 -
The Emergency Department Sedation Pilot Trial
|
N/A | |
Recruiting |
NCT04821453 -
NAVA vs. CMV Crossover in Severe BPD
|
N/A | |
Completed |
NCT03930147 -
Ventilation With ASV Mode in Children
|
N/A | |
Recruiting |
NCT05029167 -
REstrictive Versus LIberal Oxygen Strategy and Its Effect on Pulmonary Hypertension After Out-of-hospital Cardiac Arrest (RELIEPH-study)
|
N/A | |
Recruiting |
NCT04849039 -
Lung Microbiota and VAP Development (PULMIVAP)
|